Drugs
Drugs. chemically targeted radiation and antibody-based therapies all have potential to improve osteosarcoma therapy. testing 74, 78, 79, as well as in murine 80 and canine 81 systems of osteosarcoma. When osteosarcoma patients develop NEDD9 bone metastases, the normal bone is usually lysed, sometimes by the direct action of osteosarcoma cells but more commonly by recruitment of normal osteoclasts. We have evaluated the effect of zoledronic acid against osteosarcoma cell lines [This article provides important demographic information about osteosarcoma around the world.] [PMC free article] [PubMed] [Google Scholar] 2* Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1;115(7):1531C43.[This is a nice presentation of recent data from the SEER system.] [PMC free article] [PubMed] [Google Scholar] 3. Herzog CE. Protirelin Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol. 2005 Apr 1;27(4):215C8. 2005. [PubMed] [Google Scholar] 4. Protirelin Meyer WH, Malawer MM. Osteosarcoma. Clinical features and evolving surgical and chemotherapeutic strategies. Pediatric Clinics of North America. 1991;38(2):317C48. [PubMed] [Google Scholar] 5. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev. 2006 Oct 1;32(6):423C36. 2006. [PubMed] [Google Scholar] 6* Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, et al. Novel bone cancer drugs: investigational brokers and control paradigms for primary bone sarcomas (Ewing’s sarcoma and osteosarcoma). Expert Opin Investig Drugs. 2008 Nov 1;17(11):1703C15. 2008.[This article provides a nice review of recent developments for therapy, both for osteosarcoma and for Ewing sarcoma.] [PubMed] [Google Scholar] 7** Protirelin Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival–A Report From the Children’s Oncology Group. J Clin Oncol. 2008 Feb 1;26(4):633C8. 2008.[This article reports the exciting observation that mifurimide, or L-MTP-PE, provides an improvement in survival for osteosarcoma patients. This is the first clear improvement in outcomes for this disease in 20 years, and provides a basis for pursuing immune-modulatory therapies for osteosarcoma in further clinical trials.] [PubMed] [Google Scholar] 8** Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K, et al. Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients. J Clin Oncol. 2009 Feb 1;27(4):557C65. 2009.[This report underscores just how essential it is to achieve local control for all those known sites of disease when osteosarcoma recurs. It also provides much-needed hope to patients facing recurrence, since there were patients in this series who achieved long, durable remissions even after multiple relapses.] [PubMed] [Google Scholar] 9. Goorin A, Andersen J. Experience with multiagent chemotherapy for osteosarcoma. Improved outcome. Clin Orthop. 1991 Sep 1;1991(270):22C8. [PubMed] [Google Scholar] 10. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and Therapeutic Advances for Pediatric Osteosarcoma. Oncologist. 2004 Jul 1;9(4):422C41. 2004. [PubMed] [Google Scholar] 11. de Bari A, Krajbich JI, Langer F, Hamilton EL, Hubbard S. Modified Van Nes rotationplasty for osteosarcoma of the proximal tibia in children. J Bone Joint Surg Br. 1990 Nov;172-B(6):1065C9. 1990. [PubMed] [Google Scholar] 12. Gottsauner-Wolf F, Kotz R, Knahr K, Kristen H, Ritschl P, Salzer M. Rotationplasty for limb salvage in the treatment of malignant tumors at the knee. A follow-up study of seventy patients. J Bone Joint Surg Am. 1991 Oct 1;73(9):1365C75. 1991. [PubMed] [Google Scholar] 13. Fuchs N,.